ABT insider sells 387 shares at $132.66, retains 50,616 shares

Abbott Laboratories (ABT) insider transaction: Philip P. Boudreau, Abbott's EVP and CFO, sold 387 common shares at $132.66 per share in a transaction recorded on 09/01/2025, reducing his direct holdings to 50,616 shares.

Rhea-AI Filing Summary

Abbott Laboratories (ABT) insider transaction: Philip P. Boudreau, Abbott's EVP and CFO, sold 387 common shares at $132.66 per share in a transaction recorded on 09/01/2025, reducing his direct holdings to 50,616 shares. He also reports indirect beneficial ownership of 363 shares held in a Profit Sharing Trust. The filing is signed by an attorney-in-fact on behalf of Mr. Boudreau.

Positive

• Reporting is complete and compliant with Section 16 requirements, including transaction code and holdings after the sale.
• Substantial retained direct ownership of 50,616 shares indicates continued alignment with shareholders.

Negative

• Insider sold 387 shares, a disposition that reduced direct holdings (sale price reported at $132.66 per share).

Insights

Financial Analyst

TL;DR: Small, routine insider sale; remaining direct holdings remain material for alignment with shareholders.

This sale of 387 shares represents a de minimis disposition relative to total direct holdings of 50,616 shares, suggesting the transaction is likely a routine liquidity event rather than a change in confidence in the company. The report also notes a small indirect holding in a Profit Sharing Trust. No derivative transactions or other material changes to compensation structure are disclosed.

Corporate Governance Expert

TL;DR: Disclosure is complete and follows Section 16 reporting norms; transaction size is immaterial to governance stance.

The Form 4 identifies the reporting person, relationship to the issuer, transaction code and price, and residual holdings, and includes an explanatory note about the trust balance. The signature is provided via attorney-in-fact as permitted. There are no indications of coordinated sales, option exercises, or other governance events in this filing.

Insider Trade Summary

Exercise Price or Tax Liability: 387 shares

Exercise Price or Tax Liability 2 txns

Insider Boudreau Philip P

Role EVP AND CFO

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common shares without par value	387	$132.66	$51K
holding	Common shares without par value	--	--	--

Holdings After Transaction: Common shares without par value — 50,616 shares (Direct); Common shares without par value — 363 shares (Indirect, Profit Sharing Trust)

Footnotes (1)

1. F1. Balance in the Abbott Laboratories Stock Retirement Trust as of September 1, 2025.

FAQ

What transaction did Abbott Laboratories (ABT) insider Philip Boudreau report?

He reported a sale of 387 common shares at $132.66 per share, with a remaining direct holding of 50,616 shares.

Does the Form 4 show any derivative or option transactions for ABT in this filing?

No. The filing lists only a non-derivative sale of common shares and indicates indirect holdings in a Profit Sharing Trust.

How much indirect ownership does the filing report for the ABT reporting person?

The filing reports 363 shares held indirectly in a Profit Sharing Trust.

Was the Form 4 signed by the reporting person?

The signature block shows the form was signed by Philip P. Boudreau via an attorney-in-fact, consistent with the filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/03/2025 - 05:31 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Boudreau Philip P

(Last) (First) (Middle)

100 ABBOTT PARK ROAD

(Street)

ABBOTT PARK IL 60064

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ABBOTT LABORATORIES [ ABT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP AND CFO

3. Date of Earliest Transaction (Month/Day/Year)
09/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common shares without par value	09/01/2025		F		387	D	$132.66	50,616	D
Common shares without par value								363(1)	I	Profit Sharing Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Balance in the Abbott Laboratories Stock Retirement Trust as of September 1, 2025.

	/s/ Philip P. Boudreau, by Jessica H. Paik, Attorney-in-Fact	09/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.